Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.69, No.2, p.474–483, 2022 |
||
Title: Novel biochemical markers for non-invasive detection of pancreatic cancer | ||
Author: Pavel Hrabák, Jan Šoupal, Marta Kalousová, Tomáš Krechler, Michal Vočka, Tomáš Hanuš, Luboš Petruželka, Štěpán Svačina, Aleš Žák, Tomáš Zima | ||
Abstract: To identify non-invasive biomarkers of non-metastatic pancreatic cancer (PC) blood from 186 patients (PC n = 28; DM-diabetes mellitus n = 60; ChP-chronic pancreatitis n = 47; healthy controls n = 51) was analyzed for 58 candidate biomarkers. Their effectiveness to identify PC was compared with CA19-9. Panel defined by Random-forest (RF) analysis (CA19-9, AAT, IGFBP2, albumin, ALP, Reg3a, HSP27) outperforms CA 19-9 in discrimination of PC from DM (AUC 0.92 vs. 0.82). Panel (S100A11, CA72-4, AAT, CA19-9, CB, MMP-7, S100P-s, Reg3a) is better in discrimination PC from ChP than CA19-9 (AUC 0.90 vs. 0.75). Panel (MMP-7, Reg3a, sICAM1, OPG, CB, ferritin) is better in discrimination PC from healthy controls than CA 19-9 (AUC 0.89 vs. 0.78). Panel (CA19-9, S100P-pl, AAT, albumin, adiponectin, IGF-1, MMP7, S100A11) identifies PC among other groups better than CA19-9 (AUC 0.91 vs. 0.80). Panel defined by logistic regression analysis (prealbumin, IGFBP-2, DJ-1, MIC-1, CA72-4) discriminates PC from DM worse than CA19-9 (AUC 0.80 vs. 0.82). Panel (IGF-1, S100A11, Reg1alfa) outperforms CA19-9 in discrimination PC from ChP (AUC 0.76 vs. 0.75). Panel (IGF-2, S100A11, Reg3A) outperforms Ca19-9 in discrimination PC from healthy controls (AUC 0.95 vs. 0.78). Panel (albumin, AAT, S100P-serum, CRP, CA19-9, TFF1, MMP-7) outperforms CA19-9 in identification PC among other groups (AUC 0.89 vs. 0.8). The combination of biomarkers identifies PC better than CA19-9 in most cases. S100A11, Reg3A, DJ-1 were to our knowledge identified for the first time as possible serum biomarkers of PC. |
||
Keywords: serum biomarker; pancreatic cancer; non-invasive diagnosis; panel of biomarkers; S100 proteins family | ||
Published online: 11-Feb-2022 | ||
Year: 2022, Volume: 69, Issue: 2 | Page From: 474, Page To: 483 | |
doi:10.4149/neo_2022_210730N1075 |
||
|
download file |
|